Development of an evaluation model to determine disease severity in COVID-19 using basic laboratory markers
Ryosuke Maki
Clinical Laboratory Medicine, Juntendo University Urayasu Hospital, Chiba, Japan
Search for more papers by this authorCorresponding Author
Yuki Horiuchi
Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan
Correspondence
Yuki Horiuchi, Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Email: [email protected]
Search for more papers by this authorFumiaki Hayashi
Scientific Affairs, Sysmex Corporation, Kobe, Japan
Search for more papers by this authorShuko Nojiri
Medical Technology Innovation Center, Juntendo University, Tokyo, Japan
Search for more papers by this authorIkki Takehara
Reagent Engineering, Sysmex Corporation, Kobe, Japan
Search for more papers by this authorYosuke Iwasaki
Scientific Affairs, Sysmex Corporation, Kobe, Japan
Search for more papers by this authorKazunori Miyake
Clinical Laboratory Medicine, Juntendo University Urayasu Hospital, Chiba, Japan
Search for more papers by this authorTakashi Miida
Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan
Search for more papers by this authorTomohiko Ai
Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan
Search for more papers by this authorYoko Tabe
Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan
Department of Next Generation Haematology Laboratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan
Search for more papers by this authorRyosuke Maki
Clinical Laboratory Medicine, Juntendo University Urayasu Hospital, Chiba, Japan
Search for more papers by this authorCorresponding Author
Yuki Horiuchi
Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan
Correspondence
Yuki Horiuchi, Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Email: [email protected]
Search for more papers by this authorFumiaki Hayashi
Scientific Affairs, Sysmex Corporation, Kobe, Japan
Search for more papers by this authorShuko Nojiri
Medical Technology Innovation Center, Juntendo University, Tokyo, Japan
Search for more papers by this authorIkki Takehara
Reagent Engineering, Sysmex Corporation, Kobe, Japan
Search for more papers by this authorYosuke Iwasaki
Scientific Affairs, Sysmex Corporation, Kobe, Japan
Search for more papers by this authorKazunori Miyake
Clinical Laboratory Medicine, Juntendo University Urayasu Hospital, Chiba, Japan
Search for more papers by this authorTakashi Miida
Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan
Search for more papers by this authorTomohiko Ai
Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan
Search for more papers by this authorYoko Tabe
Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan
Department of Next Generation Haematology Laboratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan
Search for more papers by this authorFunding information: This work was supported in part by Japan Society for the Promotion of Science Grants-in Aid for Scientific Research (20K20230 to Yuki Horiuchi).
Open Research
DATA AVAILABILITY STATEMENT
The datasets generated in the current study are available from the corresponding author on reasonable request.
REFERENCES
- 1Alpert JS. When will the chaos end? Am J Med. 2021; 134(2): 149-150.
- 2Velavan TP, Meyer CG. Mild versus severe COVID-19: laboratory markers. Int J Infect Dis. 2020; 95: 304-307.
- 3Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chim Acta. 2020; 505: 190-191.
- 4Masotti L, Grifoni E, Pelagalli G, et al. Prognostic role of Interleukin-6/lymphocytes ratio in SARS-CoV2 related pneumonia. Int Immunopharmacol. 2021; 10(103):108435.
- 5 COVID-19 Clinical management: living guidance. https://www.who.int/publications/i/item/clinical-management-of-covid-19
- 6Cheng A, Hu L, Wang Y, et al. Diagnostic performance of initial blood urea nitrogen combined with D-dimer levels for predicting in-hospital mortality in COVID-19 patients. Int J Antimicrob Agents. 2020; 56(3):106110.
- 7Salvagno GL, Sanchis-Gomar F, Picanza A, Lippi G. Red blood cell distribution width: a simple parameter with multiple clinical applications. Crit Rev Clin Lab Sci. 2015; 52(2): 86-105.
- 8Salvagno GL, Sanchis-Gomar F, Picanza A, Lippi G. Red blood cell distribution width: a simple parameter with multiple clinical application. Crit Rev Clin Lab Sci. 2015; 52(2): 86-105.
- 9Kernan KF, Carcillo JA. Hyperferritinemia and inflammation. Int Immunol. 2017; 29(9): 401-409.
- 10Prieto-Pérez L, Fortes J, Soto C, et al. Histiocytic hyperplasia with hemophagocytosis and acute alveolar damage in COVID-19 infection. Mod Pathol. 2020; 33(11): 2139-2146.
- 11Zhang JJ, Cao YY, Tan G, et al. Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID-19 patients. Allergy. 2021; 76(2): 533-550.
- 12Linssen J, Ermens A, Berrevoets M, et al. A novel haemocytometric COVID-19 prognostic score developed and validated in an observational multicentre European hospital-based study. Elife. 2020; 26(9):e63195.
